Advertisement

Neuroleptic Malignant Syndrome

  • Stanley N. Caroff
  • Stephan C. Mann
  • E. Cabrina Campbell
  • Kenneth A. Sullivan
  • Jose Obeso
Part of the Current Clinical Neurology book series (CCNEU)

Abstract

Patient 1: A-16-year-old woman, who lives on a farm and spends time outdoors had been well with no psychiatric history until 1 week prior to admission. At that time, she developed difficulty sleeping and bizarre behavior including assault, sobbing, undressing in public, and thoughts of suicide that prompted admission to the hospital. On examination, she is labile, agitated, and delusional and experiences tactile, visual, and auditory hallucinations. She is found to have impaired recall, dyscalculia, and right-sided sensory deficits. She is started on 2 mg of haloperidol orally twice a day, and she also receives 5 mg intramuscularly for worsening agitation. Within a few hours, she develops a temperature of 39.8°, tachycardia, diaphoresis, and board-like rigidity with cogwheeling, tremors, and mutism. A generalized seizure is observed. Despite administration of diphenylhydantoin, steroids, diazepam, benztropine, and three electroconvulsive treatments, she remains rigid and unresponsive with temperatures up to 40.5°.

Keywords

Dopamine Agonist Neuroleptic Malignant Syndrome Malignant Hyperthermia Malignant Hyperthermia Delirious Mania 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Delay J, Pichot P, Lemperiere T, Elissade B, Peigne F. Un neuroleptique majeur non-phenothiaz-ine et non reserpinique, l’haloperidol, dans le traitement des psychoses. Annales Medico-Psychologique 1960;118:145–152.Google Scholar
  2. 2.
    Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980;41:79–83.PubMedGoogle Scholar
  3. 3.
    Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin N Am 1993;77:185–202.PubMedGoogle Scholar
  4. 4.
    Caroff SN, Mann SC, Campbell EC. Neuroleptic malignant syndrome. Adverse Drug Reaction Bulletin 2001;209:799–802.Google Scholar
  5. 5.
    Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002;63(suppl 4):12–19.PubMedGoogle Scholar
  6. 6.
    Caroff SN, Mann SC, Campbell EC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann 2000;30:314–321.Google Scholar
  7. 7.
    Keck PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry 1989;46:914–918.PubMedGoogle Scholar
  8. 8.
    Berardi D, Amore M, Keck PE Jr, Troia M, Dell’Atti M. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case control study. Biol Psychiatry 1998;44:748–754.PubMedCrossRefGoogle Scholar
  9. 9.
    White DAC, Robins AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry 1991;158:419–421.PubMedCrossRefGoogle Scholar
  10. 10.
    Caroff SN, Mann SC, McCarthy M, Naser J, Rynn M, Morrison M. Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J Clin Psychopharmacol 1998;18:349–351.PubMedCrossRefGoogle Scholar
  11. 11.
    Caroff SN, Rosenberg H, Mann SC, Campbell EC, Gliatto MF, Sullivan KA. Neuroleptic malignant syndrome in the perioperative setting. Am J Anesthesiol 2001;28:387–393.Google Scholar
  12. 12.
    Mann SC, Caroff SN, Fricchione G, Campbell EC. Central dopamine hypoactivity and the patho-genesis of the neuroleptic malignant syndrome. Psychiatr Ann 2000;30:363–374.Google Scholar
  13. 13.
    Ueda M, Hamamoto M, Nagayama H, Okubo S, Amemiya S, Katayama Y. Biochemical alterations during medication withdrawal in Parkinson’s disease with and without neuroleptic malignant-like syndrome. J Neurol Neurosurg Psychiatry 2001;71:111–113.PubMedCrossRefGoogle Scholar
  14. 14.
    Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res 1995;27:233–244.CrossRefGoogle Scholar
  15. 15.
    Suzuki A, Kondo T, Otani K, et al. Association of the TaqIA polymorphism of the dopamine D2 receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry 2001;158:1714–1716.PubMedCrossRefGoogle Scholar
  16. 16.
    Ram A, Cao Q, Keck PE, et al. Structural change in the dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome. Am J Med Genet 1995;60:228–230.PubMedCrossRefGoogle Scholar
  17. 17.
    Gurrera RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol 2002;25:183–193.PubMedCrossRefGoogle Scholar
  18. 18.
    Caroff SN, Mann SC, Sullivan K, Macfadden W. Drug-induced hypermetabolic syndromes. In: Ohnishi ST, Ohnishi T, eds. Malignant Hyperthermia: A Genetic Membrane Disease. CRC, Boca Raton, Florida: 1994;118–132.Google Scholar
  19. 19.
    Velamoor VR, Norman RM, Caroff SN, Mann SC, Sullivan KA, Antelo RE. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 1994;182:168–173.PubMedCrossRefGoogle Scholar
  20. 20.
    Caroff SN, Mann SC. Neuroleptic malignant syndrome. Psychopharmacol Bull 1988;24:25–29.PubMedGoogle Scholar
  21. 21.
    Caroff SN, Mann SC, Keck PE Jr., Francis A. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 2000;20:257–259.PubMedCrossRefGoogle Scholar
  22. 22.
    Caroff SN, Mann SC, Gliatto MF, Sullivan KA, Campbell EC. Psychiatric manifestations of acute viral encephalitis. Psychiatr Ann 2001;31:193–204.Google Scholar
  23. 23.
    Caroff SN, Mann SC, Lazarus A, Sullivan KA, Macfadden W. Neuroleptic malignant syndrome: diagnostic issues. Psychiatr Ann 1991;21:130–147.Google Scholar
  24. 24.
    Mann SC, Caroff SN, Bleier HR, Welz WK, Kling MA, Hayashida M. Lethal catatonia. Am J Psychiatry 1986;143:1374–1381.PubMedGoogle Scholar
  25. 25.
    Fricchione G, Mann SC, Caroff SN. Catatonia, lethal catatonia and neuroleptic malignant syndrome. Psychiatr Ann 2000;30:347–355.Google Scholar
  26. 26.
    Davis JM, Caroff SN, Mann SC. Treatment of neuroleptic malignant syndrome. Psychiatr Ann 2000;30:325–331.Google Scholar
  27. 27.
    Caroff SN, Mann SC, Campbell EC. Risk of fatal heatstroke after hospitalization. Psychiatr Serv 2000;51:938.PubMedCrossRefGoogle Scholar
  28. 28.
    Keck PE Jr, Arnold LM. The serotonin syndrome. Psychiatr Ann 2000;30:333–343.Google Scholar
  29. 29.
    Caroff SN, Mann SC, Keck PE Jr. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry 1998;44:378–381.PubMedCrossRefGoogle Scholar
  30. 30.
    Rodriguez M, Luquin MR, Lera G, Delgado G, Salazar JM, Obeso JA. Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion. Mov Disord 1990;5:170–172.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2005

Authors and Affiliations

  • Stanley N. Caroff
    • 1
  • Stephan C. Mann
    • 1
  • E. Cabrina Campbell
    • 1
  • Kenneth A. Sullivan
    • 1
  • Jose Obeso
    • 2
  1. 1.Department of PsychiatryUniversity of Pennsylvania School of Medicine and the Department of Veterans Affairs Medical CenterPhiladelphia
  2. 2.Department of Neurology, Clinica Universitaria and Medical SchoolUniversity of NavarraPamplonaSpain

Personalised recommendations